Table 2 Demographic and clinical characteristics of patients with PTEN pathogenic variant (mutPTEN) vs wild-type PTEN (wtPTEN).

From: PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma

 

Wt (n = 545)

Mut (n = 57)

P

Median age

60 (19–92)

56 (35–81)

0.56

Female

315 (57.8)

35 (61.4)

0.61

Race

Asian

106 (19.4)

9 (15.8)

0.06

Black

19 (3.5)

6 (10.5)

Hispanic

84 (15.4)

9 (15.8)

White

314 (57.5)

33 (57.9)

Others

22 (4.0)

0

PS

0–1

474 (87.0)

48 (84.2)

0.71

2–4

49 (9.0)

7 (12.3)

Unknown

22 (4.0)

2 (3.5)

CCI

1 (0–9)

2 (0–6)

0.07

Treatment

Yes

429 (78.7)

45 (78.9)

0.97

No

116 (21.3)

12 (21.2)

Histology

LMS

142 (26.1)

32 (56.1)

<0.001

UPS

124 (22.8)

12 (21.1)

LPS

74 (13.6)

4 (7.0)

Others

205 (37.6)

9 (15.8)

RB1

wt

440 (80.7)

31 (54.4)

<0.001

mut

105 (19.3)

26 (45.6)

TP53

wt

294 (53.9)

12 (21.1)

<0.001

mut

251 (46.1)

45 (78.9)

CDKN2A

wt

410 (75.2)

53 (93.0)

0.002

mut

135 (24.8)

4 (7.0)

ATRX

wt

349 (64.0)

31 (54.4)

0.30

mut

58 (10.6)

9 (15.8)

unknown

138 (25.3)

17 (29.8)

  1. The number inside the parenthesis represents the percent except for median age.
  2. PS performance status, CCI Charlson comorbidity index, LMS leiomyosarcoma, UPS undifferentiated pleomorphic sarcoma, LPS liposarcoma.
Back to article page